Unaudited Interim Consolidated Statements of Cash Flows - USD ($) $ in Millions		9 Months Ended
		Sep. 30, 2025	Sep. 30, 2024
Operating Activities
Net earnings (loss)		$ (1,173)	$ 388
Adjustments to reconcile net earnings (loss) to net cash provided by (used in) operating activities
Asset impairments	[1]	1,486	39
Depreciation, amortization and accretion		585	634
Pension and postretirement net periodic benefit cost		5	4
Pension and postretirement contributions		(38)	(39)
Deferred income taxes, net		(118)	12
(Gain) loss on disposition of businesses and assets, net		(3)	(11)
Stock-based compensation		19	23
Undistributed earnings in unconsolidated affiliates		3	(33)
Other, net		40	13
Operating cash provided by (used in) discontinued operations		6	(6)
Changes in operating assets and liabilities
Trade receivables - third party and affiliates, net		96	(109)
Inventories		158	(177)
Other assets		131	59
Trade payables - third party and affiliates		3	(33)
Other liabilities		(312)	(314)
Net cash provided by (used in) operating activities		894	472
Investing Activities
Capital expenditures on property, plant and equipment		(259)	(330)
Proceeds from sale of businesses and assets, net		(7)	0
Settlement of cross-currency swap agreement		0	17
Other, net		7	(29)
Net cash provided by (used in) investing activities		(245)	(342)
Financing Activities
Net change in short-term borrowings with maturities of 3 months or less		3	133
Proceeds from short-term borrowings		606	160
Repayments of short-term borrowings		(555)	(418)
Proceeds from long-term debt		2,926	299
Repayments of long-term debt		(3,060)	(1,019)
Stock option exercises		0	1
Common stock dividends		(9)	(230)
Distributions/dividends to noncontrolling interests		(22)	(25)
Other, net		(78)	(25)
Net cash provided by (used in) financing activities		(189)	(1,124)
Exchange rate effects on cash and cash equivalents		18	2
Net increase (decrease) in cash and cash equivalents		478	(992)
Cash and cash equivalents as of beginning of period		962	1,805
Cash and cash equivalents as of end of period		$ 1,440	$ 813

[1] Primarily related to non-cash impairment losses on goodwill and certain trade names, primarily Zytel® during the three and nine months ended September 30, 2025 (Note 5) and on certain trade names, primarily Zytel® during the three and nine months ended September 30, 2024.